fda compounding semaglutide crackdown 2025 news The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the The growing availability of compounded

Its important to not that Semaglutide GLP-1 injections are not meant to be a quick-fix solution for dropping excess weight

The TGA says the eye disorder non-arteritic anterior ischaemic optic neuropathy (NAION) may result in permanent visual impairment and no treatment has been shown to improve visual acuity outcomes after the condition develops

This schedule is anecdotal and was not tested in the published human trials

Because retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), it is classified as an investigational medicinal product (IMP)

Until a true head-to-head study is completed, retatrutides relative effectiveness remains highly suggestive but not definitively established